

STEMI With Multivessel CAD – Immediate or Staged Revascularization?

Ian C Gilchrist, MD, FACC, MSCAI

Professor of Medicine

Penn State's Hershey Medical Center

Heart & Vascular Institute

Hershey, PA

lan.C.Gilchrist.MD@gmail.com

@Radial_icg



CME Disclosure Statement





Research Funding

1.Duke Clinical Research Institute2.Svelte Medical3.Ablative Solutions4.CSL Behring5.Shaanxi Micot

Equity Ownership 1. Verve Medical, Inc




Nothing relevant to talk


Case Presentation



Evening of July 4th, 55-year-old man presented with 4 hours of chest pain. P=50, BP=70/40. EKG obtained at triage.



Acute inferior wall myocardial infarction






Angiography & Stent of RCA





MiamiValves.org



Angiography Left Coronary








Clean it up, or leave it for later?



Survival \downarrow with \uparrow CAD Burden



20% with either ≥50% LMCA or ≥90% in non-IRA




COMPLETE Trial



Multivessel vs Culprit Only Primary PCI: Primary Outcomes

CV Death or New MI

CV Death, New MI, or IDR



Mehta SR et al, N Engl J Med 2019; 381(15):1411

IDR: Ischemia Driven Revascularization CV: Cardiovascular MI: Myocardial Infarction



Mortality: Culprit v Multi-Vessel PCI

	Multi	vessel	Culp	rit Only				
Study	Events	Total	Events	Total	Risk Ratio	RR	95% CI	V
HELP AMI, 2004	1	52	0	17		1.00	0.04-23.44	
Politi, 2010	10	130	13	84		0.50	0.23-1.08	
Ghani, 2012	4	79	0	40		4.58	0.25-83.09	
PRAMI, 2013	12	234	16	231	-#-	0.74	0.36-1.53	
DANAMI-3, 2015	15	314	11	313	. <u>+-</u> -	1.36	0.63-2.91	
PRAGUE-13, 2015	6	106	7	108	<u> </u>	0.87	0.30-2.51	
CVLPRIT, 2015	4	150	10	146		0.39	0.12-1.21	
Hamza, 2016	1	50	4	50		0.25	0.03-2.16	
COMPARE ACUTE, 2017	4	295	10	590		0.80	0.25-2.53	
COMPLETE, 2019	96	2016	106	2025		0.91	0.70-1.19	
Random Effects Model 3426			3604		0.85	0.68-1.05		
Heterogeneity: <i>1</i> ² =0%, τ ² =0, <i>p</i> = 0.53								
					0.1 0.5 1 2 10 Favors Multi-vessel Favors Culprit-vessel			

Revascularization Guidelines 2021



Recommendations for Revascularization of Non-Infarct Artery in STEMI

Lawton JS, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. *J Am Coll Cardiol.* 2022;79:e21-e129.



Multi-vessel PCI in Cardiogenic Shock

Cohort Studies (N≈5,500 patients)


	Multives	sel PCI	Culprit PCI		Mortality				
	Events	Total	Events	Total	<30 days				
IABP-Shock II	75	167	119	284	÷.				
ALKK	81	173	201	562	÷				
KAMIR	13	124	56	386					
Yang et al.	19	60	68	278					
Cavender et al.	20	43	42	156					
EHS-PCI	40	82	95	254	+				
NCDR	158	433	737	2654					
Overall	406	1082	1318	4574					
Heterogeneity: $l^2=31\%$, $\tau^2=0.007$, $p=0.19$									
Test for overal	l effect: p	=0.001		Γ	Aulti-vessel Culpr PCI only				


Despite the hypothetical value for complete re-vascularization in shock, cohort studies suggest otherwise.

de Waha S et al, Eur Heart J: Acute Cardiovasc Care 2018; 7(1):28

ʻit

Randomized Trial in Cardiogenic Shock






Lawton JS, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. J Am Coll Cardiol. 2022;79:e21-e129.



p=NS

Physiology in Acute MI



1.00

FFR in non-culprit artery

N=101, STEMI=76, NSTEM=25

FFR at baseline (acute) FFR at follow up $(35 \pm 4 \text{ days})$


No difference in non-infarct artery

Ntalianis A et al. J Am Coll Cardiol Intv 2010; 3(12):1274-1281.


Physiology vs Angiography for Non-Culprit



FRAME-AMI: Primary end: Composite of time to death, MI, or re-vascularization



https://doi.org/10.1093/eurheartj/ehac763



Thank You

Questions?

Email: icg1@psu.edu ian.c.gilchrist.md@gmail.com igilchrist@pennstatehealth.psu.edu

Twitter: @Radial_ICG





